BJMO - volume 18, issue 8, december 2024
J. Dekervel MD, PhD
In September of 2024, the yearly ESMO congress took place in Barcelona. In this article, new insights that were presented in the field of gastrointestinal oncology are covered, with emphasis on the practice-changing or practice-informing new data.
(BELG J MED ONCOL 2024;18(8):311–316)
Read moreBJMO - volume 18, issue 7, november 2024
L. Smets MSc, K. Haustermans MD, PhD, A. Wolthuis MD, PhD, G. Bislenghi MD, PhD, E. van Cutsem MD, PhD, L. Debrun BSc, G. de Hertogh MD, PhD, A. D’Hoore MD, PhD, R. Dresen MD, PhD, G. Rasschaert MD, X. Sagaert MD, PhD, S. Tejpar MD, PhD, F. van Herpe MD, J. Dekervel MD, PhD
The multidisciplinary management of rectal cancer is an evolving field, and these guidelines seek to offer direction for treating this condition. A tailored treatment approach should be based on a multi-disciplinary tumour board discussion taking into account tumour staging, patient performance status, and expectations. Patients with node-negative T1 rectal cancer can be managed by a local excision. In patients with early rectal cancer, primary surgery is the standard-of-care. In some of these patients, an organ-sparing approach by long-course chemoradiotherapy can be an alternative. A total neoadjuvant therapy (TNT)-approach consisting of a combination of (chemo)radiotherapy and chemotherapy is preferred for locally advanced disease.
(BELG J MED ONCOL 2024;18(7):271–278)
Read moreBJMO - volume 14, issue 7, november 2020
S. Cappuyns MD, J. Dekervel MD, PhD, E. van Cutsem MD, PhD, S. Tejpar MD, PhD, C. Verslype MD, PhD
Advanced hepatocellular carcinoma, known for its dismal prognosis, is a disease that is challenging to treat. For almost a decade, sorafenib was the only available treatment. However, the last two to three years have witnessed a true revolution in systemic treatment options for this lethal disease. Several targeted therapies with mostly anti-angiogenic properties have been developed and immunotherapy has made its entrance into the field. Furthermore, a growing understanding of the molecular pathways involved in hepatocarcinogenesis and new insights in tumour-immunobiology have led to the development of rational combination therapies, showing very promising results in a myriad of ongoing clinical trials. Here we review the latest developments and discuss the main consequences for clinical practice.
(BELG J MED ONCOL 2020;14(7):339-46)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
